DA-3091 has the potential to be used safely and efficaciously in a biweekly dosing regimen.

No abstract

Osteoporosis is a progressive metabolic bone disease, which decreases the bone mass and deteriorates the microstructure of the bone tissue, increasing the vulnerability of the bone to risk of fracture [1]. Certainly, various treatments have studied for osteoporosis to improve bone density include oestrogen hormone replacement therapy, calcitonin, and bisphosphonate [2]. A recombinant parathyroid hormone (rhPTH 1-34) is the last drug of choice for the treatment of osteoporosis for patients for whom all other drug regimens have failed [3]. It has advantages of activating osteoblasts as an anabolic agent and inhibiting osteoclasts simultaneously [4]. However, rhPTH 1-34 exhibited rapid elimination with a short half-life after subcutaneous injection in the body and requires daily injections in clinical practice [5]. Thus, a new strategy to prolong the therapeutic effect of rhPTH 1-34 is required in patients to avoid repeated injections [6]. A sustained release